CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset

Published: 2/12/2019
CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset
Source: WWW.PRNEWSWIRE.COM

The newly founded relationship will combine the research and development ingenuity of Fapon Biopharma with the state-of-art biologics manufacturing services offered by CMAB CMAB will provide a full range of development and manufacturing services for Fapon Biopharma's biologic drug project...

Read more
Related news
Comment
FACEBOOK